Special Issue of PharmacoEconomics on Major Depressive Disorders
PharmacoEconomics (2021) 39:617
Managing Principal Paul E. Greenberg and Senior Advisor Tammy Sisitsky served as guest editors for a themed issue of PharmacoEconomics on major depressive disorders (MDDs). The issue provided perspectives from the international pharmacoeconomic community on epidemiologic estimates of MDD and its treatment, economic burden, cost effectiveness of treatment, and methodological challenges.
In addition to curating the collection of papers by researchers from around the world, Mr. Greenberg and Ms. Sisitsky contributed an introduction with commentary on the fundamental changes caused by the devastating spread of coronavirus disease 2019 (COVID-19). They noted that the special edition marked another milestone in their 30-year study of the economic burden of “this widespread, debilitating, and economically burdensome mental illness,” and that the collected research represented recent advances in understanding the complexities associated with the burden of MDD and its treatment, while pointing to new research directions.
Three of the issue’s 11 articles also had Analysis Group coauthors:
- “The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers” (Managing Principal Paul E. Greenberg, Principal Dave Nellesen, and Manager David Proudman)
- “Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA” (Managing Principal Patrick Lefebvre, Vice President Dominic Pilon, Manager Maryia Zhdanava, Associate Tom Cornwall, Associate Laura Morrison, and Research Professional Maude Vermette‑Laforme from Analysis Group, and Jennifer Voelker, Abigail I. Nash, Kruti Joshi, and Cheryl Neslusan from Janssen Scientific Affairs, LLC)
- “The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)” (Managing Principal Paul E. Greenberg, Senior Advisor Tamar Sisitsky, Vice President Andree-Anne Fournier, Associate Mark Simes, and Senior Analyst Richard Berman, with Harvard Medical School Professor Ronald C. Kessler)